Analyses of cost-effectiveness of migraine therapies should consider multiple measures.

Journal of managed care pharmacy : JMCP

Volumn 9, Issue 3, 2003, Pages

  Silberstein, Stephen D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN AGONIST;

BIOASSAY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; HUMAN; METHODOLOGY; MIGRAINE; NOTE; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; HUMANS; MIGRAINE DISORDERS; RECURRENCE; SEROTONIN AGONISTS; TIME FACTORS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 0642368625     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2003.9.3.279     Document Type: Note

References (0)